公开(公告)号：US09913844B2

公开(公告)日：2018-03-13

申请号：US14777873

申请日：2014-03-19

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Laure De Parseval

IPC: A61K31/506 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  C12Q1/68

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  A61K2300/00

Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

公开(公告)号：US20180221370A1

公开(公告)日：2018-08-09

申请号：US15875031

申请日：2018-01-19

Applicant: Novartis AG

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Laure De Parseval

IPC: A61K31/506 ,  A61K9/20 ,  A61K9/00 ,  C12Q1/6886 ,  A61K9/48 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377

Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

公开(公告)号：US20160296520A1

公开(公告)日：2016-10-13

申请号：US14777873

申请日：2014-03-19

Applicant: NOVARTIS AG

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Laure De Parseval

IPC: A61K31/506 ,  A61K31/519 ,  C12Q1/68 ,  A61K9/00 ,  A61K9/48 ,  A61K9/20 ,  A61K31/4184 ,  A61K31/53

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  A61K2300/00

Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

Abstract translation: 通过从患者获得肿瘤样品并在包含BRAF，CRAF，CCND1，CDK4，HER2，IGF-1R，cMET的基因组中进行遗传改变来测试用于治疗增殖性疾病的B-Raf抑制剂的抗逆性 ，FGFR1，FGFR2，FGFR3 EGFR，MAP2K1，MAP2K2，NRAS，KRAS HRAS，PTEN，PIK3CA和P16，并且施用包含B-Raf抑制剂和克服对B-Raf抑制剂的抗性的第二抑制剂的药物联合疗法， 基于在肿瘤样品中发现的遗传变异选择第二抑制剂。